{"id":"ad26-mos-hiv","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ad26.Mos.HIV is a recombinant adenovirus vector-based vaccine designed to elicit an immune response against HIV.","oneSentence":"HIV vaccine","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:49:22.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV prevention"}]},"trialDetails":[{"nctId":"NCT02788045","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-07-08","conditions":"Healthy","enrollment":201},{"nctId":"NCT02919306","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-09","conditions":"Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT02315703","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2014-12-22","conditions":"Healthy","enrollment":393},{"nctId":"NCT02685020","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-03-28","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Ad26.Mos.HIV","genericName":"Ad26.Mos.HIV","companyName":"Janssen Vaccines & Prevention B.V.","companyId":"janssen-vaccines-prevention-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"HIV vaccine Used for HIV prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}